MT1JP and hepatocellular carcinoma: Several of these selected molecules are already identified as being either diagnostic (VSP45, TERT, EBF2, hsa-miR-324-5p, hsa-miR-130a-3p, hsa-miR-200a-3p, hsa-miR-106b-5p, hsa-21-5p, hsa-424-5p), prognostic (CAP2, TRMT6, MT1JP, hsa-miR-10b-5p, hsa-miR-139-3p, hsa-miR-101, hsa-miR-122-5p, hsa-miR-1285-3p, hsa-miR-203a-3p), recurrence-related (CD34, hsa-miR-183), or therapeutic (AKR1B10, SLC25A4, CYP2B7, FBXL18, hsa-miR-146a-5p, hsa-miR-34a, hsa-miR-122, hsa-miR-671-5p) biomarker candidates for HCC [23–27].